Pure Global
NCT06334562

The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery

An Observational Study on the Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery
The Fourth Affiliated Hospital of Zhejiang University School of Medicine·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Neuromuscular Blockade
Drug/Device/Intervention
SUGAMMADEX SODIUM 100 Mg in 1 mL
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Aug 31, 2025
Enrollment
80 participants
Primary outcome

Muscle relaxation recovery time

Summary

This study aims to compare the use of sugammadex (domestic) and neostigmine for antagonism
 after thoracic surgery, and observe the effect of sugammadex (domestic) on neuromuscular
 blockade antagonism after thoracic surgery, in order to provide a basis for optimizing the
 use of muscle relaxants and their antagonists during anesthesia.

ICD-10 classifications
Skeletal muscle relaxants [neuromuscular blocking agents]Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]Other neuromuscular dysfunction of bladderNeuromuscular dysfunction of bladder, unspecifiedNeuromuscular scoliosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06334562
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06334562 through Pure Global AI's free database. This phase not specified trial is sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine and is currently Not yet recruiting. The study focuses on Neuromuscular Blockade. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.